Europe Cancer Genomic Testing Market was valued at USD 3.1 Billion in 2022 and is projected to reach USD 6.7 Billion by 2030, growing at a CAGR of 10.4% from 2024 to 2030.
The Europe Cancer Genomic Testing Market is rapidly evolving, driven by an increasing demand for personalized medicine and the growing need to understand genetic mutations in cancer patients. This market focuses on the use of genomic technologies to examine DNA sequences to identify specific genetic alterations that drive cancer. The key players in this field include pharmaceutical companies, diagnostics companies, and biotechnology firms that are advancing technologies and services in genomic testing.
The demand for cancer genomic testing in Europe has been significantly impacted by the rise in cancer cases across the region, alongside increasing public and private sector investment in health innovation. One of the major drivers for this market's expansion is the demand for targeted therapies, which require precise genetic data to design individualized treatment plans. By analyzing the genetic mutations of a patient’s cancer, doctors can better predict how the cancer will behave and which treatments will be the most effective.
In particular, the use of next-generation sequencing (NGS) technology has made genomic testing more efficient and accurate. This advanced technology allows for a more comprehensive analysis of genetic mutations in a shorter period of time. This efficiency is highly attractive to hospitals and healthcare providers looking to offer personalized cancer treatment plans while reducing time-to-diagnosis.
Industries such as biotechnology, pharmaceuticals, and healthcare providers require precise and rapid cancer genomic testing solutions to develop drugs, optimize clinical trials, and offer effective treatment plans. For pharmaceutical companies, genomic testing plays a critical role in the development of oncology drugs. By identifying genetic markers that predict how a cancer will respond to a particular drug, companies can develop more effective treatments that are tailored to individual patients.
In addition to the growing demand for personalized medicine, the regulatory environment in Europe supports advancements in cancer genomic testing, ensuring high standards of safety and efficacy. As these technologies continue to evolve, it’s expected that the market for cancer genomic testing in Europe will grow significantly, with more healthcare systems integrating these diagnostic tools into routine care for cancer patients.
Get an In-Depth Research Analysis of the Europe Cancer Genomic Testing Market Size And Forecast [2025-2032]
Myriad Genetics
Centogene AG
Color Genomics
Quest Diagnostics
23andMe Inc.
Gene By Gene Ltd.
LabCorp
Positive Bioscience
Bio-Rad Laboratories
Illumina
Inc.
Agilent Technologies
Thermo Fisher Scientific
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Europe Cancer Genomic Testing Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Europe Cancer Genomic Testing Market
Next-Generation Sequencing (NGS)
Polymerase Chain Reaction (PCR)
Fluorescent In Situ Hybridization (FISH)
Microarray Analysis
Other Genomic Testing Methods
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Leukemia
Other Cancers
Tissue Biopsies
Blood Sample-Based Testing
Urine-Based Tests
Saliva Tests
Hospitals
Diagnostic Laboratories
Research Institutions
Pharmaceutical Companies
Risk Assessment
Patient Stratification
Therapeutic Decision Making
Monitoring Treatment Response
Recurrence and Progression Monitoring
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
For More Information or Query, Visit @ Cancer Genomic Testing Market Research Analysis
1. Introduction of the Europe Cancer Genomic Testing Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Europe Cancer Genomic Testing Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Europe Cancer Genomic Testing Market, By Type
6. Europe Cancer Genomic Testing Market, By Application
7. Europe Cancer Genomic Testing Market, By Geography
Europe
Germany
UK
France
8. Europe Cancer Genomic Testing Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Research and Consulting firm servicing over 5000+ clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/